Sébastien LecommandouxCollège de FranceInnovation technologique Liliane Bettencourt (2024-2025)Année 2024-2025Colloque - Advancing Biomaterials: Biomimetic and Biohybrid InnovationsMolly Stevens : Designing and translating new materials for advanced therapies and disease detectionMolly StevensJohn Black Professor of Bionanoscience, University of OxfordRésuméThis talk will present recent advances in therapeutic and biosensing materials, with a focus on translational pipelines for clinical application. We have developed scalable fabrication methods to create complex 3D architectures and biofunctionalized surfaces with spatially organized biochemical and topographical cues. Our delivery platforms include high-molecular-weight polymer carriers for saRNA therapeutics and photo-responsive nanoreactors inspired by circadian rhythms. We are also exploring bioinspired soft robotics for targeted, stimuli-responsive drug delivery.In diagnostics, we are engineering functionalized nanoparticles for in vivo disease detection, including colorimetric nanoprobes for visual readouts and CRISPR-based, preamplification-free RNA detection (CrisprZyme). We have developed Raman microspectroscopy tools and machine learning techniques for hyperspectral unmixing, enabling the analysis of live-cell and organoid models and tracking nanomedicines in vivo.A key innovation is our SPARTA™ platform, which enables high-throughput, label-free characterization of single nanoparticles, supporting the development of nanoparticle therapeutics and exosome diagnostics.This talk will explore how these technologies are advancing biomedical innovation and how we are establishing translational pathways to bring them into the clinic—while striving to make healthcare solutions more accessible and equitable. Molly StevensProfessor Dame Molly Stevens FREng FRS is John Black Professor of Bionanoscience at the University of Oxford (Department of Physiology, Anatomy and Genetics and Institute of Biomedical Engineering) and part-time Professor at Imperial College London and the Karolinska Institute. Professor Stevens' multidisciplinary research balances the investigation of fundamental science with the development of technologies and designer biomaterials to address some of the major healthcare challenges across diagnostics, advanced therapeutics and regenerative medicine. The impact of her work is recognised by numerous accolades, including the 2023 Novonordisk Prize. Professor Stevens' work has a strong translational drive, focussed on translating scientific innovation into practical solutions to benefit patients and society. She is a serial entrepreneur and the founder of four spin-off companies in the diagnostics, advanced therapeutics, and regenerative medicine space. She has been recently appointed as Oxford University Champion for Women and Diversity in Entrepreneurships.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related